Schouls Leo, Schot Corrie, de Voer Richarda M, van der Klis Fiona, Knol Mirjam, Tcherniaeva Irina, Berbers Guy
Infectious Diseases Research, Diagnostics and Laboratory Surveillance (IDS), National Institute for Public Health and the Environment, 3721MA Bilthoven, The Netherlands.
Immunology of Infectious Diseases and Vaccines (IIV), National Institute for Public Health and the Environment, 3721MA Bilthoven, The Netherlands.
Vaccines (Basel). 2020 Jun 30;8(3):347. doi: 10.3390/vaccines8030347.
In 1993, a serotype b (Hib) conjugate vaccine was introduced in the Dutch national immunization program, resulting in a sharp decrease in invasive Hib disease. We used a population-based set of serum samples collected in the Netherlands in 2006-2007 (Pienter-II, 5696 sera) to assess the concentration of antibodies to the capsular polysaccharide of Hib, and compared the results with those obtained from a similar set collected in 1995-1996 (Pienter-I, 7837 sera). Post-primary vaccination serum samples from children aged 6-11 months from the Pienter-II study contained approximately 4-fold lower anti-Hib antibody concentrations than samples from children from the Pienter-I study. No such difference was found in post-booster samples from children older than 11 months of age. In Pienter-II, the proportion of children aged 6-11 months with anti-Hib antibody concentrations below the putative protective concentration of 0.15 µg/mL was 30%, which is significantly higher than in the Pienter-I study (12%). Fewer children in the Pienter-II group developed antibodies able to kill Hib in a serum bactericidal assay compared to the Pienter-I children. The cause of the lagged response in Pienter-II children remain uncertain, but lack of natural boosting, interference by the acellular pertussis vaccine, combining vaccines and acceleration of the schedule may have contributed.
1993年，一种b型流感嗜血杆菌（Hib）结合疫苗被纳入荷兰国家免疫规划，侵袭性Hib疾病的发病率急剧下降。我们使用了2006 - 2007年在荷兰收集的一组基于人群的血清样本（Pienter-II，5696份血清）来评估针对Hib荚膜多糖的抗体浓度，并将结果与1995 - 1996年收集的类似样本（Pienter-I，7837份血清）的结果进行比较。Pienter-II研究中6至11个月大儿童的初次接种后血清样本中的抗Hib抗体浓度比Pienter-I研究中儿童的样本低约4倍。在11个月以上儿童的加强接种后样本中未发现此类差异。在Pienter-II中，抗Hib抗体浓度低于假定保护浓度0.15 µg/mL的6至11个月大儿童的比例为30%，显著高于Pienter-I研究中的比例（12%）。与Pienter-I组儿童相比，Pienter-II组中在血清杀菌试验中产生能够杀死Hib的抗体的儿童较少。Pienter-II组儿童反应滞后的原因尚不确定，但缺乏自然加强、无细胞百日咳疫苗的干扰、联合疫苗以及接种程序的加速可能都起到了一定作用。
